16.14
+5.49%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Nurix Therapeutics
From its filings with the US Securities and Exchange Commission
Nurix Therapeutics is based in Brisbane, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker NRIX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 30 November 2025, it reported revenue of $84.0m and a net loss of $264.5m. At that date it held total assets of $688.1m and shareholders' equity of $538.7m. By business, Collaboration revenue brought in 64.3% of revenue, followed by License revenue at 35.7%.
We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully artificial intelligence (AI)-integrated discovery engine capable of tackling any protein class, and coupled with leading ligase expertise, Nurix has built a significant advantage in translating the science of protein degradation into clinical advancements with the aim of establishing degrader-based treatments at the forefront of patient care. Our wholly owned, clinical stage pipeline includes three investigational drug candidates designed with the goal to be first-in-class or best-in-class therapeutics: bexobrutideg (NX-5948), a highly selective degrader of Bruton’s tyrosine kinase (BTK); zelebrudomide (NX-2127), a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. We are also advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in our preclinical pipeline.
Quoted from its 10-K, filed 28 Jan 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 24 Jul 2020
- Employees
- 317
- Website
- nurixtx.com ↗
- Head office
- 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Ms. Julia GregoryIndependent Chairman of the Board$371,616
- Dr. Arthur SandsPresident, Chief Executive Officer, Director, since 2014$5.8m
- Mr. Hans van HouteChief Financial Officer, since 2020$2.0m
- Dr. Gwenn HansenChief Scientific Officer$2.0m
- Dr. Christine RingChief Legal Officer, Chief Compliance Officer, Secretary$2.0m
- Mr. John NorthcottChief Commercial Officer
- Dr. Roy BaynesIndependent Director
- Mr. Anil KapurIndependent Director$821,988
- Dr. David LaceyIndependent Director$355,762
- Ms. Judith ReinsdorfIndependent Director$342,012
- Mr. Edward SaltzmanIndependent Director$336,179
- Mr. Paul SilvaIndependent Director$338,679
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 51
- Environment
- 54
- Social
- 60
- Governance
- 39
- Women in the workforce
- 52%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Nurix Therapeutics Inc excels in developing innovative therapeutics using its proprietary DNA-encoded libraries and targeted protein modulation platform.
- This strength allows the company to differentiate itself from competitors and potentially deliver breakthrough treatments for various diseases.
- The company boasts a highly skilled R&D team consisting of experienced scientists and researchers.
- Their expertise enables Nurix Therapeutics Inc to maintain a competitive edge in the field of targeted protein degradation and develop novel therapies that address unmet medical needs.
- Nurix Therapeutics Inc has successfully established strategic partnerships with industry leaders, academia, and biotech companies.
- These partnerships provide the company with access to additional resources, expertise, and funding opportunities, allowing for accelerated research and development timelines.
Weaknesses
- Currently, Nurix Therapeutics Inc has a limited number of product candidates in its pipeline.
- This lack of diversity in their product portfolio poses a risk in terms of potential revenue generation and market presence.
- The company heavily relies on external research funding, such as grants and collaborations, to support its R&D efforts.
- Any disruption or reduction in funding sources could impact the company's ability to progress its pipeline and meet its objectives.
Opportunities
- The increasing interest in targeted protein degradation therapies presents a significant opportunity for Nurix Therapeutics Inc.
- As the field gains recognition and acceptance, the company can leverage its expertise to capture a share of the growing market.
- Nurix Therapeutics Inc has the potential to expand its therapeutic focus beyond its current areas of interest.
- By leveraging its platform and expertise, the company can explore new therapeutic targets and address emerging medical needs.
Threats
- The biotechnology industry is highly competitive, with numerous established players and emerging startups.
- Nurix Therapeutics Inc faces the threat of competitors developing similar or more advanced technologies and therapies.
- Developing and commercializing therapeutics involves navigating complex regulatory processes.
- Nurix Therapeutics Inc may face delays or setbacks due to evolving regulatory requirements, safety concerns, and changing market dynamics.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.